Loading...
NPI 1033239413 · Fenton, MO · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Thyroid Specialty Laboratory Inc is a clinical medical laboratory provider located in Fenton, Missouri. This profile covers 88 Medicare and 99 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Thyroid Specialty Laboratory Inc |
| Address | 1636 Headland Dr |
| City | Fenton |
| State | MO |
| ZIP | 63026 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | March 30, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $30.2M |
| Medicare | $3.2M |
This provider’s payer mix is heavily skewed toward Medicaid: reported Medicaid revenue is $30.2M versus Medicare revenue of $3.2M, so Medicaid clearly dominates the lab’s billed volume and overall revenue stream. Analysts should treat this entity as a Medicaid-focused operator when evaluating its business footprint and contracting leverage.
THYROID SPECIALTY LABORATORY INC has been enumerated since 2007-03-30 (~19 years ago), indicating a long-standing NPI presence; that tenure is consistent with an established laboratory operation rather than a short-term or recently formed testing service. The longevity supports the interpretation of high cumulative Medicaid claims as an enduring business pattern rather than a transient spike.
The mix of high-revenue CPT/HCPCS codes shows a core service line built around molecular infectious-disease testing and high-throughput virology panels: Medicare and Medicaid top codes include 87798, 87502, a large set of amplified nucleic acid probe tests (for influenza, SARS-CoV-2, strep, MRSA, etc.), and definitive drug testing under G0483. This combination suggests the lab runs broad molecular diagnostics at scale (including respiratory and sexually transmitted infection panels) and also offers definitive toxicology services.
Revenue concentration is high on both payers: the top 3 Medicare codes account for 58.5% of total Medicare revenue, and the top 3 Medicaid codes account for 55.3% of total Medicaid revenue. On Medicare the highest single-code driver is 87798 ($1.4M, 44.9% of Medicare revenue) alongside 87502 ($243.5K, 8.0%) and G0483 ($170.4K, 5.6%); these three codes dominate Medicare receipts and define the lab’s Medicare service profile.
On Medicaid the largest individual drivers are 87798 ($10.5M, 36.1%), U0004 ($3.9M, 13.3%), and 87502 ($1.7M, 5.9%), and those three together account for the precomputed 55.3% share of Medicaid revenue. The Medicaid billing pattern indicates heavy reliance on a few high-volume molecular and COVID-related codes, consistent with a centralized, high-throughput testing model.
Competitive standing diverges by payer: for Medicaid the lab is frequently the top in-state performer—87798, U0004, 87502, G0483 and many other high-volume codes rank #1 in-state and are labeled as “100th percentile; extreme outlier, far above typical state volume” or similarly notable state outliers—indicating a dominant statewide role for these tests. This pattern implies strong market share and capacity for Medicaid testing within Missouri.
Nationally for Medicare the picture is mixed: 87502 ranks #15 of 3547 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code) and several molecular codes (for example 87635 and 87651) are in the 99th percentile or similarly “notably above typical national volume,” showing the lab has unusually high national volumes for specific tests. However, total Medicare revenue is only $3.2M, so despite extreme outlier status on some codes the lab’s overall Medicare footprint remains modest compared with its Medicaid scale.
Operational implications from the code set include demonstrated capacity for high-throughput SARS-CoV-2 testing (U0004, U0005, 87635) and broad respiratory/STD molecular panels, plus definitive multi-class drug testing (G0483). Together these signals point to a laboratory configured for volume-driven, automated molecular and toxicology workflows that serve large Medicaid testing contracts and large-scale public health needs.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
88 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 40,140 | $30 | $1.4M |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 2,620 | $90 | $243.5K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 710 | $240 | $170.4K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 4,180 | $30 | $125.4K |
| 87556 | The lab analyst performs a test for Mycobacterium tuberculosis using amplified nucleic acid probe technique. Mycobacteria tuberculosis are sometimes called acid fast bacteria because of the special… | 2,560 | $40 | $105K |
| 87563 | he lab analyst performs a test on a patient specimen such as blood, for Mycoplasma genitalium antigen detection using amplified nucleic acid probe technique. | 2,690 | $30 | $91.6K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 2,610 | $30 | $88.9K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 2,610 | $30 | $88.8K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 1,670 | $50 | $83.5K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 1,090 | $70 | $80.8K |
Showing 1–10 of 88
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 88 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
88 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87798 | 1 | 10 | 380 | $30 | $140.7K |
| U0004 | 2 | 10 | 570 | $70 | $125.8K |
| P9603 | 6 | 10 | 9,150 | $1 | $122K |
| G0483 | 1 | 10 | 190 | $240 | $65.9K |
| 87498 | 1 | 10 | 1,610 | $30 | $55.1K |
| 87486 | 1 | 10 | 1,540 | $30 | $52.7K |
| 87541 | 1 | 10 | 1,540 | $30 | $52.6K |
| 87556 | 1 | 10 | 1,290 | $40 | $52.5K |
| 87581 | 1 | 10 | 1,540 | $30 | $52.5K |
| 87532 | 1 | 10 | 1,490 | $30 | $50.9K |
Showing 1–10 of 88
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
99 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 84,300 | $130 | $10.5M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 58,890 | $70 | $3.9M |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 48,980 | $40 | $1.7M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 39,660 | $40 | $1.5M |
| 87498 | A lab tests a patient’s specimen to provide a definitive diagnosis of meningitis by amplified probe technique. | 53,710 | $20 | $913K |
| 87532 | The lab analyst performs a test for Herpes virus 6 using amplified nucleic acid probe technique. Herpes virus 6, also called human herpes virus 6 or HHV6, causes a common childhood rash, roseola, and… | 49,990 | $20 | $899.8K |
| 87496 | The lab analyst performs a test for cytomegalovirus, or CMV, using amplified nucleic acid probe technique. CMV may cause severe illness in newborns and immunocompromised patients. | 49,090 | $20 | $883.7K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 51,200 | $20 | $870.4K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 5,270 | $160 | $833.1K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 46,930 | $20 | $797.7K |
Showing 1–10 of 99
How this provider's Medicaid billing volume and revenue compare to other Missouri providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Missouri median
99 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 1 | 10 | 960 | $60 | $584.3K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 1 | 30 | 80 | $120 | $440.4K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 127 | 240 | 1,740 | $40 | $353.4K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 134 | 320 | 980 | $40 | $352.7K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 20 | 740 | $70 | $279.4K |
| 87529 | The lab analyst performs a test for Herpes simplex virus, HSV, using amplified nucleic acid probe technique. HSV causes clusters of blisters, or vesicles, on different parts of the body and spreads… | 1 | 10 | 8,370 | $30 | $237.9K |
| 87532 | The lab analyst performs a test for Herpes virus 6 using amplified nucleic acid probe technique. Herpes virus 6, also called human herpes virus 6 or HHV6, causes a common childhood rash, roseola, and… | 1 | 10 | 1,330 | $20 | $232.6K |
| 87496 | The lab analyst performs a test for cytomegalovirus, or CMV, using amplified nucleic acid probe technique. CMV may cause severe illness in newborns and immunocompromised patients. | 1 | 10 | 1,330 | $20 | $225.9K |
| 87541 | The lab analyst performs a test for the bacteria Legionella pneumophila using amplified nucleic acid probe technique. L. pneumophila can inhabit facility water and air conditioning systems and may… | 1 | 10 | 1,300 | $20 | $206.4K |
| 87498 | A lab tests a patient’s specimen to provide a definitive diagnosis of meningitis by amplified probe technique. | 1 | 10 | 120 | $20 | $193.6K |
Showing 1–10 of 99
Other providers in the same ZIP code as Thyroid Specialty Laboratory Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Ssm Medical Group, Inc. | MO | Multi-Specialty Clinic/Center | $0 | $19.4M |
| Option Care Enterprises, Inc. | MO | Home Infusion Therapy Pharmacy | $0 | $11.2M |
| Ssm Health Care St. Louis | MO | General Acute Care Hospital | $0 | $7.7M |
| Alternative Hospice LLC | MO | Community Based Hospice Care Agency | $0 | $4.1M |
| Solutions Lab And Health Care Services LLC | MO | Clinical Medical Laboratory | $967.7K | $1.4M |
| Jeffrey Petersen | MO | Dermatology Physician | $616.1K | $0 |
| Fenton Fire Protection District | MO | Land Ambulance | $291.6K | $304.6K |
| Ssm St Clare Surgical Center LLC | MO | Ambulatory Surgical Clinic/Center | $398K | $0 |
| Brent Davidson | MO | Ophthalmology Physician | $251.9K | $0 |
| Michael Boedefeld | MO | Pain Medicine (Anesthesiology) Physician | $176.7K | $4.2K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.